Oncternal Q1 net loss $8.4M; ONCT-534 cohort fully enrolled; cash runway into Q1 2025

Oncternal Therapeutics, Inc.

2024-Q1 EPS reported -$2.83 revenue$569,000

Net loss $8.4M ($2.83 per share); grant revenue $0.6M; total operating expenses $9.3M including $1.4M stock-based compensation.
Cash, cash equivalents & short-term investments $27.0M as of March 31, 2024; no debt; projected runway into Q1 2025.
Phase 1/2 ONCT-534 for advanced prostate cancer: fourth cohort (300 mg/day) fully enrolled; initial data expected late Q2 2024.
Phase 1/2 ONCT-808 (ROR1 CAR T) for aggressive B-cell lymphoma open and enrolling; clinical update expected mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oncternal Therapeutics, Inc. reported for the quarter ended March 31, 2024 results: revenue $0.6 million, net income Net loss for the first quarter was $8.4 million, or a net loss of $2.83 per share, EPS $2.83 per share, basic and diluted.

Period: for the quarter ended March 31, 2024
Revenue: $0.6 million
Net income: Net loss for the first quarter was $8.4 million, or a net loss of $2.83 per share
EPS: $2.83 per share, basic and diluted
Result: reported results

Exact text from the filing

T cell therapy ‒ Clinical data update in mid-2024 ‒ Additional clinical data readouts in the fourth quarter of 2024 First Quarter 2024 Financial Results Our grant revenue was $0.6 million for the first quarter ended March 31, 2024. Our total operating expenses for the first quarter ended March 31, 2024 were $9.3 million, including $1.4 million in non-cash

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-056882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.